Clinical efficacy and risk assessment of sivelestat sodium in the treatment of acute lung injury
基于西维来司他钠治疗急性肺损伤的临床疗效及风险评估

摘要

目的 观察西维来司他钠治疗急性肺挫伤的临床疗效及相关风险因素。方法 选取 2023年5月-2025年7月符合筛选条件的的急性肺挫伤患者60例，回顾性收集患者临床资料，根据不同治疗方案将患者分为对照组（常规治疗方案）和试验组（常规治疗方案+西维来司他钠），各30例。分析比较两组患者一般基线资料、治疗前和治疗后血清炎症因子指标水平、动脉血气指标水平、生活自理能力评分、住院时长以及病死率等指标，采用χ2检验、线性回归分析西维来司他钠治疗急性肺挫伤影响患者预后相关风险因素。结果 本研究共纳入60例患者，治疗前PCT 试验组＞对照组，差异有统计学意义（P＜0.05）试验组；PCT治疗后＜治疗前，差异有统计学意义（P＜0.05）；两组BADL评分均为治疗后＞治疗前，差异有统计学意义（P＜0.05）；治疗前SaO₂对照组＞试验组，差异有统计学意义（P＜0.05）；对照组PaO₂治疗前＜治疗后，差异有统计学意义（P＜0.05）；单因素分析结果：创伤性休克、肝功能异常是试验组影响患者预后的相关风险因素，差异有统计学意义（P＜0.05），线性回归分析结果：肝功能异常是试验组影响患者预后的独立风险因素，差异有统计学意义（P＜0.05）。结论 西维来司他钠能减轻急性肺挫伤患者的炎症反应，改善患者生活自理能力，治疗期间需提高对患者肝功能指标的关注，以辅助优化治疗方案。

Abstract

Objective To observe the clinical efficacy of sivelestat sodium in the treatment of acute pulmonary contusion and the related risk factors.
Methods Sixty patients with acute pulmonary contusion who met the screening criteria from May 2023 to July 2025 were selected. The clinical data of the patients were retrospectively collected. According to different treatment regimens, the patients were divided into the control group (conventional treatment regimen) and the experimental group (conventional treatment regimen + siverestat sodium), with 30 cases in each group. The general baseline data, serum inflammatory factor index levels before and after treatment, arterial blood gas index levels, self-care ability scores, length of hospital stay and mortality rate of the two groups of patients were analyzed and compared. The χ2 test and linear regression were used to analyze the risk factors related to the prognosis of patients with acute pulmonary contusion treated with siverestat sodium.
Results A total of 60 patients were included in this study. Before treatment, the PCT in the experimental group was greater than that in the control group, and the difference was statistically significant (P < 0.05). After PCT treatment, the value was less than that before treatment, and the difference was statistically significant (P < 0.05). The BADL scores of both groups were higher after treatment than before treatment, and the difference was statistically significant (P < 0.05). Before treatment, the SaO₂ in the control group was greater than that in the experimental group, and the difference was statistically significant (P < 0.05). In the control group, PaO₂ was less before treatment than after treatment, and the difference was statistically significant (P < 0.05). Univariate analysis results: Traumatic shock and abnormal liver function were the related risk factors affecting the prognosis of patients in the experimental group, and the difference was statistically significant (P < 0.05). Linear regression analysis results: Abnormal liver function was an independent risk factor affecting the prognosis of patients in the experimental group, and the difference was statistically significant (P < 0.05).
Conclusion   Sivelestat sodium can alleviate the inflammatory response in patients with acute pulmonary contusion and improve their self-care ability. During the treatment period, more attention should be paid to the liver function indicators of patients to assist in optimizing the treatment plan.